Filterlex Medical is a cardiovascular medical device startup based in Caesarea, Israel, led by founder and CEO Sigal Eli. Its core product, CAPTIS®, is a next‑generation full‑body embolic protection device intended to reduce the risk of stroke and other complications during catheter‑based left‑heart procedures such as TAVR. The CAPTIS device is deployed and retrieved, is securely positioned in the aorta to protect its surface, requires no additional arterial access, and is designed not to interfere with procedural workflow. The company joined the Alon MedTech Ventures incubator in 2016. Filterlex closed a $6M Series A1 round (backers undisclosed) and intends to use the funds to accelerate implementation of its CAPTIS clinical program. Filterlex Medical is developing CAPTIS, an embolic protection device intended to reduce the risk of stroke and other complications during catheter-based structural heart procedures. CAPTIS won the best innovation award at the PCR 2019 innovation competition in Paris and the company received a $200,000 grant from the Jon DeHaan Foundation. The company began operating in June 2016 at the Alon MedTech Ventures incubator in Yokneam, Israel. The incubator is owned by Dr. Shimon Eckhouse, described in the article as a technological entrepreneur and an investor in the field of medical devices. Led by founder, inventor and CEO Sigal Eli alongside Prof. Giora Weisz, Filterlex has operated independently since August 2018. The company completed a $3M Series A financing in 2019.

Total raised

$9M

Funding rounds

2

Latest round

Series A

Latest activity

Nov 2021